A new patent drug for the treatment of Type -2 diabetes——Jinlida Granules
National Varieties for Medical Insurance Drugs
National Key New Product
High-tech Product designated by the Ministry of Science and Technology of the P.R.C
National Protected Varieties of Traditional Chinese Medicine
It is reported that Type-2 diabetes has become a major threat to human health. There are 113.9 million patients with diabetes in adults over 18 years old and about 493.4 million people with pre-diabetes in China. Jinlida Granules has definite curative effect in regulating glucose and lipid metabolism, improving glucose tolerance, reducing insulin resistance and decreasing complications.
linical evidence-based study on metformin combined with Jinlida Granules in the treatment of Type-2 diabetes
Leading Hospital: Guang'anmen Hospital, China Academy of Chinese Medical Science (CACMS)
Cooperating Hospitals: Xiyuan Hospital of China Academy of Chinese Medical Science (CACMS), Affiliated Hospital of Changchun University of Traditional Chinese Medicine,
Shanxi Provincial Hospital of Traditional Chinese Medicine, Affiliated Hospital of Shanxi University of Traditional Chinese Medicine, Bethune International Peace Hospital, etc.
On the basis of diet control, exercise therapy and stable dose of metformin, combined application of Jinlida Granules can better control the glycosylated hemoglobin in patients with Type-2 diabetes. The Jinlida Granules group had potential therapeutic advantages in reducing waist circumference reducing complications, and improving the functions of islet β - cells.